×

Uh-oh, it looks like your Internet Explorer is out of date.

For a better shopping experience, please upgrade now.

Tumor Targeting in Cancer Therapy / Edition 1
     

Tumor Targeting in Cancer Therapy / Edition 1

by Michel Page
 

See All Formats & Editions

ISBN-10: 161737251X

ISBN-13: 9781617372513

Pub. Date: 11/19/2010

Publisher: Springer-Verlag New York, LLC

After many years of vigorous effort, the use of antibodies to target tumors has become highly successful both clinically and commercially. In Tumor Targeting in Cancer Therapy, Dr. Michel Pagé and a panel of authoritative experts from the drug industry, clinics, and academia introduce the principles and techniques of tumor targeting and critically survey their

Overview

After many years of vigorous effort, the use of antibodies to target tumors has become highly successful both clinically and commercially. In Tumor Targeting in Cancer Therapy, Dr. Michel Pagé and a panel of authoritative experts from the drug industry, clinics, and academia introduce the principles and techniques of tumor targeting and critically survey their applications from laboratory to bedside. By concisely synthesizing the many technical details, the authors illuminate this innovative technique, ranging from the fundamentals of drug targeting and in vivo and in vitro experimentation, to such emerging therapeutic uses as radioimmunotherapy, radioimmunodetection, therapy with cytotoxic antibodies, immunotoxins, enzyme prodrug immunotherapy, and immunotherapeutics with fusion proteins. There are also reviews of targeting tumors with radioimmunoconjugates, photodynamic therapy, and magnetic drugs, as well as discussions of the internalization of antibodies, bioconjugation and biodistribution, the use of cytotoxic drugs, and the pros and cons of targeting by antibody or ligand.

Comprehensive and practical, Tumor Targeting in Cancer Therapy summarizes the essentials of tumor targeting as it is practiced today and provides all those engaged in experimental and clinical cancer research the critically established information needed to evaluate new technologies, investigate novel therapeutic agents, and apply them in relevant clinical practice.

Product Details

ISBN-13:
9781617372513
Publisher:
Springer-Verlag New York, LLC
Publication date:
11/19/2010
Series:
Cancer Drug Discovery and Development Series
Edition description:
Softcover reprint of hardcover 1st ed. 2002
Pages:
463
Product dimensions:
7.01(w) x 10.00(h) x 0.39(d)

Table of Contents

Part I. A Review

The Current Status of Tumor Targeting: A Review
Tarunendu Ghose

Clinical Applications of Targeted Therapeutics
Tarunendu Ghose

Part II. Targeting Tumors with Drug Antibody Conjugates

Targeting the CD22 Receptor with RNA Damaging Agents
Huaitian Liu, Dianne L. Newton, Hans J. Hansen, Stanislaw M. Mikulski, David M. Goldenberg, Edward A. Sausville, and Susanna M. Rybak

The Development of Liposomes for Enhanced Delivery of Chemotherapeutics to Tumors
Paul Tardi, Ludger Ickenstein, Marcel Bally, and Lawrence Mayer

Overcoming Multiple Drug Resistance with Anti-Pgp Carrier
Brigitte Pagé and Michel Pagé

Targeting with Transferrin, Mandip Singh

Synthesis and Evaluation of Paclitaxel Immunoconjugate with Antitumor Activity In Vitro
Jairo Jaime Correa and Michel Pagé

The Use of Drug-Monoclonal Antibody Conjugates for the Treatment of Cancer
Geoffrey A. Pietersz and Ian F. C. McKenzie

Part III. Targeting Tumors with Antibodies

Targeting Vascular Endothelium with Antibodies
Przemek Twardowski and Kim Margolin

Targeting B-Cell Non-Hodgkin's Lymphoma with Monoclonal Antibodies
Christian Buske and W. Hiddemann

From Bench to Bedside: Development of Rituximab (Rituxan ®), A Monoclonal Antibody for the Therapy of Non-Hodgkin's Lymphoma
Roland Newman

Mylotarg: The First Antibody-Targeted Chemotherapy Agent
Philip R. Hamann and Mark S. Berger

Part IV. Targeting Tumors with Radioimmunoconjugates

188Rhenium-Labeled Trisuccin-DCh2HuCC49 as a Radioimmunotherapy Model in Nude Mice
Ahmad Safavy and Donald J. Buchsbaum

Part V. Targeting Tumors with Immunotoxins

General Approach for Targeting Toxins
Manish Monga, Richard A. Messman, and Edward A. Sausville

Antibody-Toxin Conjugates: Chemistry of Couplingand Purification
Silvana Canevari, Maria Ines Colnaghi, Luigi Cattel, and Franco Dosio

Shiga-Like Toxins as Targeted Anticancer Agents
Paul LaPointe and Jean Gariépy

Part VI. Targeting Tumors with Antibody-Enzyme Conjugates (ADEPT)

Antibody-Directed Enzyme Prodrug Therapy with Carboxypeptidase G2: Clinical Studies
Kenneth D. Bagshawe

Part VII. Photodynamic Therapy

Photodynamic Therapy: Targeting Cancer Cells with Photosensitizer-Bioconjugates
Cynthia M. Allen, Wesley M. Sharman, and Johan E. van Lier

Tumor Targeting Using PEG-m-THPC for Photodynamic Therapy in a Rat Ovarian-Cancer Model
René Hornung

Part VIII. Targeting Tumors with Magnetic Drugs

Targeting Tumors with Magnetic Drugs
Andreas S. Lübbe, Christian Bergemann, and Christoph Alexiou

Part IX. Principles and Techniques in Targeting

Internalization of Antibodies
Jairo Jaime Correa

Bioconjugation and Biodistribution
Francesco M. Veronese and Paulo Caliceti

Principles of Antitumor Targeting of Cytotoxic Drugs
Gene M. Dubowchik

Targeting by Antibody or Ligand: Which Is Better?
Douglas A. Lapp

Index

Customer Reviews

Average Review:

Post to your social network

     

Most Helpful Customer Reviews

See all customer reviews